

**Advanced Chemical Industries PLC**

Condensed Interim Financial Statements  
2nd quarter ended report 2025-2026  
for the six months period ended on 31 December 2025


**Advanced Chemical Industries PLC**  
**Statement of financial position**  
**Unaudited**

	Note	Figures in '000' Taka	
		As at 31 December 2025	As at 30 June 2025
<b>Assets</b>			
Property, plant and equipment	2	20,675,275	20,383,667
Right-of-use assets		879,437	672,691
Investments	3	4,871,667	4,038,094
Intangible assets		10,428	10,428
Biological assets		61,977	58,443
<b>Non-current assets</b>		<b>26,498,784</b>	<b>25,163,323</b>
Inventories	4	10,421,731	9,539,984
Trade receivables	5	5,666,593	4,645,139
Other receivables		891,503	698,206
Inter-company receivables	6	45,213,637	41,055,886
Current tax assets		848,968	999,458
Advances, deposits and prepayments	7	2,523,377	1,811,171
Cash and cash equivalents		2,747,802	1,540,164
<b>Current assets</b>		<b>68,313,611</b>	<b>60,290,008</b>
<b>Total assets</b>		<b>94,812,395</b>	<b>85,453,331</b>
<b>Equity</b>			
Share capital		878,318	878,318
Share premium		457,210	457,210
Reserves		6,036,457	5,970,353
Retained earnings		25,257,546	22,496,338
<b>Total equity</b>		<b>32,629,532</b>	<b>29,802,220</b>
<b>Liabilities</b>			
Employee benefits	8	1,768,830	1,762,277
Long term borrowings	9	1,846,671	1,523,822
Non-current portion of lease liabilities		654,289	485,361
Deferred tax liabilities		274,100	225,041
<b>Non-current liabilities</b>		<b>4,543,889</b>	<b>3,996,501</b>
Bank overdraft		10,508,268	7,810,856
Loans and borrowings	10	31,098,420	28,471,845
Current portion of lease liabilities		231,962	198,988
Trade payables		2,313,888	3,126,500
Inter-company payables	11	7,147,671	6,893,326
Other payables	12	6,108,678	5,142,590
Unclaimed/unpaid dividend account		230,086	10,507
<b>Current liabilities</b>		<b>57,638,974</b>	<b>51,654,610</b>
<b>Total liabilities</b>		<b>62,182,863</b>	<b>55,651,111</b>
<b>Total equity and liabilities</b>		<b>94,812,395</b>	<b>85,453,331</b>
<b>Net asset value (NAV) per share (in Taka)</b>		<b>371.50</b>	<b>339.31</b>

  
 Managing Director

  
 Director

  
 Chief Financial Officer


  
 Company Secretary

**Advanced Chemical Industries PLC**  
**Statement of profit or loss**  
**Unaudited**

Figures in '000' Taka

	Note	For the half year ended from		For the 2nd quarter ended from	
		July 2025	July 2024	October 2025	October 2024
		to December 2025	to December 2024	to December 2025	to December 2024
Revenue	13	27,077,673	22,401,549	13,986,289	12,262,690
Cost of sales	14	(16,887,888)	(13,936,591)	(8,899,813)	(7,691,913)
<b>Gross profit</b>		<b>10,189,784</b>	<b>8,464,958</b>	<b>5,086,476</b>	<b>4,570,777</b>
Administrative, selling and distribution expenses	15	(6,980,961)	(5,887,557)	(3,549,464)	(3,214,466)
Other income		1,349,558	1,293,062	337,399	1,259,962
<b>Operating profit</b>		<b>4,558,382</b>	<b>3,870,464</b>	<b>1,874,412</b>	<b>2,616,273</b>
Net finance costs		(500,811)	(656,011)	(326,622)	(379,247)
<b>Profit before contribution to WPPF</b>		<b>4,057,571</b>	<b>3,214,453</b>	<b>1,547,789</b>	<b>2,237,027</b>
Contribution to WPPF		(202,879)	(160,723)	(77,389)	(111,851)
<b>Profit before tax</b>		<b>3,854,693</b>	<b>3,053,730</b>	<b>1,470,400</b>	<b>2,125,175</b>
Income tax expense		(873,904)	(676,174)	(324,490)	(478,636)
<b>Profit after tax</b>		<b>2,980,788</b>	<b>2,377,556</b>	<b>1,145,909</b>	<b>1,646,539</b>
<b>Earnings per share</b>					
Basic and diluted earnings per share (EPS) (in Taka)		33.94	27.07	13.05	18.75

  
 Managing Director

  
 Director

  
 Chief Financial Officer

  
 Company Secretary

**Advanced Chemical Industries PLC**  
**Statement of profit or loss and other comprehensive income**  
**Unaudited**

	Figures in '000' Taka			
	For the half year ended from		For the 2nd quarter ended from	
	July 2025 to December 2025	July 2024 to December 2024	October 2025 to December 2025	October 2024 to December 2024
Profit after tax	2,980,788	2,377,556	1,145,909	1,646,539
<b>Other comprehensive income:</b>				
Change in fair value of FVOCI financial assets	77,769	(8,944)	(10,052)	2,904
Income tax on FVOCI financial assets	(11,665)	1,342	1,508	(436)
<b>Other comprehensive income, net of tax</b>	<b>66,104</b>	<b>(7,603)</b>	<b>(8,545)</b>	<b>2,468</b>
<b>Total comprehensive income</b>	<b>3,046,892</b>	<b>2,369,953</b>	<b>1,137,365</b>	<b>1,649,007</b>

**Advanced Chemical Industries PLC**  
Statement of changes in equity  
Unaudited

	Figures in '000' Taka							
	For the half year ended from July 2025 to December 2025							
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total equity
<b>Balance at 1 July 2025</b>	878,318	457,210	-	1,671	248,634	5,720,048	22,496,338	29,802,220
<b>Total comprehensive income</b>								
Profit after tax	-	-	-	-	-	-	2,980,788	2,980,788
Other comprehensive income, net of tax	-	-	-	-	66,104	-	-	66,104
<b>Total comprehensive income</b>	-	-	-	-	66,104	-	2,980,788	3,046,892
<b>Transaction with owners of the Company</b>								
Stock dividend	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	(219,580)	(219,580)
<b>Total transactions with owners of the Company</b>	-	-	-	-	-	-	(219,580)	(219,580)
<b>Balance at 31 December 2025</b>	<b>878,318</b>	<b>457,210</b>	<b>-</b>	<b>1,671</b>	<b>314,738</b>	<b>5,720,048</b>	<b>25,257,546</b>	<b>32,629,532</b>
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	FVOCI reserve	Revaluation reserve	Retained earnings	Total equity
<b>Balance at 1 July 2024</b>	762,056	402,310	56,854	1,671	291,665	4,584,170	18,765,010	24,863,737
<b>Total comprehensive income</b>								
Profit after tax	-	-	-	-	-	-	2,377,556	2,377,556
Other comprehensive income, net of tax	-	-	-	-	(7,603)	-	-	(7,603)
<b>Total comprehensive income</b>	-	-	-	-	(7,603)	-	2,377,556	2,369,953
<b>Transaction with owners of the Company</b>								
Issuance of merger consideration share	1,954	54,900	(56,854)	-	-	-	-	-
Stock dividend	114,602	-	-	-	-	-	(114,602)	-
Cash dividend	-	-	-	-	-	-	(152,802)	(152,802)
<b>Total transactions with owners of the Company</b>	<b>116,555</b>	<b>54,900</b>	<b>(56,854)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(267,404)</b>	<b>(152,802)</b>
<b>Balance at 31 December 2024</b>	<b>878,612</b>	<b>457,210</b>	<b>-</b>	<b>1,671</b>	<b>284,063</b>	<b>4,584,170</b>	<b>20,875,162</b>	<b>27,080,888</b>

**Advanced Chemical Industries PLC**  
**Statement of cash flows**  
**Unaudited**

	Figures in '000' Taka	
	For the half year ended from	
	July 2025 to December 2025	July 2024 to December 2024
<b>Cash flows from operating activities</b>		
Cash receipts from customers and others	26,366,818	21,892,483
Cash paid to suppliers and employees	(24,906,843)	(19,043,906)
<b>Cash generated from / (used in) operating activities</b>	<b>1,459,975</b>	<b>2,848,577</b>
Paid to WPPF	(272,960)	(209,270)
Finance costs paid	(116,452)	(416,138)
Income tax paid	(686,021)	(832,286)
	(1,075,433)	(1,457,694)
<b>Net cash from / (used in) operating activities*</b>	<b>16</b>	<b>1,390,883</b>
<b>Cash flows from investing activities</b>		
Acquisition of property, plant and equipment	(755,897)	(952,471)
Sale proceeds from property, plant and equipment	164	2,660
Purchase of biological assets	(7,005)	(6,746)
Dividend received	974,880	959,543
Investment	(755,598)	(59,473)
<b>Net cash from / (used in) investing activities</b>	<b>(543,456)</b>	<b>(56,488)</b>
<b>Cash flows from financing activities</b>		
Inter-company debts received/(paid)	(3,903,405)	(4,324,781)
Payment for lease liabilities	(111,049)	(98,782)
Short-term borrowing received/(paid)	2,414,727	1,104,623
Long-term borrowing received/(paid)	268,662	(79,548)
<b>Net cash from / (used in) financing activities</b>	<b>(1,331,065)</b>	<b>(3,398,489)</b>
Net increase / (decrease) in cash and cash equivalents	(1,489,979)	(2,064,091)
Opening cash and cash equivalents	(6,270,692)	(4,816,516)
Effect of movements in exchange rates on cash held	205	240
<b>Closing cash and cash equivalents</b>	<b>(7,760,467)</b>	<b>(6,880,366)</b>
<b>Closing balance represents</b>		
Cash and cash equivalents	2,747,802	1,781,611
Bank overdraft	(10,508,268)	(8,661,978)
	(7,760,467)	(6,880,366)
<b>Net operating cash flow per share (NOCFPS) (in Taka)</b>	<b>4.38</b>	<b>15.84</b>

\*See Note 16 for reconciliation of net operating cash flow.

**Advanced Chemical Industries PLC**  
**Consolidated statement of financial position**  
**Unaudited**

	Note	Figures in '000' Taka	
		As at 31 December 2025	As at 30 June 2025
<b>Assets</b>			
Property, plant and equipment	2 (a)	37,846,917	37,761,072
Right-of-use assets		2,974,684	2,914,579
Equity-accounted investees		2,135,385	2,760,624
Other investments		1,822,099	1,197,150
Intangible assets		1,315,843	1,383,389
Biological assets		61,977	58,443
Deferred tax assets		1,375,621	1,087,556
<b>Non-current assets</b>		<b>47,532,527</b>	<b>47,162,813</b>
Inventories	4 (a)	26,107,254	24,549,867
Trade receivables	5 (a)	27,420,696	22,370,726
Other receivables		1,018,193	983,975
Advances, deposits and prepayments	7 (a)	6,285,800	4,774,301
Current tax assets		288,651	691,835
Short term investments		185,590	206,784
Cash and cash equivalents		4,404,510	3,245,939
<b>Current assets</b>		<b>65,710,694</b>	<b>56,823,427</b>
<b>Total assets</b>		<b>113,243,220</b>	<b>103,986,240</b>
<b>Equity</b>			
Share capital		878,318	878,318
Share premium		1,309,016	1,309,016
Reserves		8,029,164	7,955,672
Accumulated loss		(2,249,785)	(2,094,077)
Equity attributable to owners of the Company		7,966,713	8,048,929
Non-controlling interests		1,662,987	1,718,886
<b>Total equity</b>		<b>9,629,701</b>	<b>9,767,815</b>
<b>Liabilities</b>			
Employee benefits	8 (a)	2,287,426	2,232,080
Long term borrowings	9 (a)	5,528,833	5,548,425
Non-current portion of lease liabilities		2,390,081	2,350,503
<b>Non-current liabilities</b>		<b>10,206,340</b>	<b>10,131,008</b>
Bank overdraft		8,674,392	8,034,699
Loans and borrowings	10 (a)	62,361,990	55,474,007
Current portion of lease liabilities		677,340	625,874
Trade payables		8,851,169	9,530,298
Other payables	12 (a)	12,333,745	10,410,334
Unclaimed/unpaid dividend account		508,544	12,205
<b>Current liabilities</b>		<b>93,407,179</b>	<b>84,087,417</b>
<b>Total liabilities</b>		<b>103,613,520</b>	<b>94,218,425</b>
<b>Total equity and liabilities</b>		<b>113,243,220</b>	<b>103,986,240</b>
<b>Net asset value (NAV) per share (in Taka)</b>	18	<b>90.70</b>	<b>91.64</b>

  
**Managing Director**

  
**Director**

  
**Chief Financial Officer**

  
**Company Secretary**


**Advanced Chemical Industries PLC**  
**Consolidated statement of profit or loss**  
**Unaudited**

	Note	Figures in '000' Taka			
		For the half year ended from		For the 2nd quarter ended from	
		July 2025 to December 2025	July 2024 to December 2024	October 2025 to December 2025	October 2024 to December 2024
Revenue	13 (a)	77,943,911	66,197,421	40,984,089	36,487,726
Cost of sales	14 (a)	(57,164,705)	(49,534,668)	(30,066,562)	(27,310,449)
<b>Gross profit</b>		<b>20,779,206</b>	<b>16,662,753</b>	<b>10,917,528</b>	<b>9,177,277</b>
Administrative, selling and distribution expenses	15 (a)	(14,159,251)	(11,679,431)	(7,383,827)	(6,277,599)
Other income		227,575	207,952	127,974	124,918
<b>Operating profit</b>		<b>6,847,531</b>	<b>5,191,274</b>	<b>3,661,674</b>	<b>3,024,596</b>
Share of the profit of equity accounted investees		148,503	257,313	53,962	147,222
Net finance costs		(4,921,919)	(4,436,700)	(2,562,941)	(2,310,498)
<b>Profit before contribution to WPPF</b>		<b>2,074,115</b>	<b>1,011,887</b>	<b>1,152,695</b>	<b>861,320</b>
Contribution to WPPF		(321,764)	(253,341)	(150,501)	(169,291)
<b>Profit before tax</b>		<b>1,752,351</b>	<b>758,546</b>	<b>1,002,194</b>	<b>692,028</b>
Income tax expense		(1,450,342)	(1,404,579)	(763,448)	(868,918)
<b>Profit/ (loss) after tax</b>		<b>302,009</b>	<b>(646,033)</b>	<b>238,746</b>	<b>(176,889)</b>
<b>Profit/ (loss) attributable to:</b>					
Owners of the Company		63,871	(702,093)	29,780	(278,530)
Non-controlling interests		238,138	56,060	208,966	101,641
<b>Profit/ (loss) after tax</b>		<b>302,009</b>	<b>(646,033)</b>	<b>238,746</b>	<b>(176,889)</b>
<b>Earnings per share</b>					
Basic and diluted earnings per share (EPS) (in Taka)	18	0.73	(7.99)	0.34	(3.17)

  
 \_\_\_\_\_  
 Managing Director

  
 \_\_\_\_\_  
 Director

  
 \_\_\_\_\_  
 Chief Financial Officer

  
 \_\_\_\_\_  
 Company Secretary

**Advanced Chemical Industries PLC**  
**Consolidated statement of profit or loss and other comprehensive income**  
**Unaudited**

	Figures in '000' Taka			
	For the half year ended from		For the 2nd quarter ended from	
	July 2025 to December 2025	July 2024 to December 2024	October 2025 to December 2025	October 2024 to December 2024
Profit/ (loss) after tax	302,009	(646,033)	238,746	(176,889)
<b>Other comprehensive income:</b>				
Foreign operations - foreign currency translation differences	14,589	(115,321)	(14,790)	(45,019)
Change in fair value of FVOCI financial assets	63,556	(532)	(34,441)	(11,152)
Income tax on other comprehensive income	(9,533)	80	5,166	1,673
<b>Other comprehensive income, net of tax</b>	<b>68,611</b>	<b>(115,774)</b>	<b>(44,065)</b>	<b>(54,499)</b>
<b>Total comprehensive income</b>	<b>370,620</b>	<b>(761,806)</b>	<b>194,680</b>	<b>(231,388)</b>
<b>Total comprehensive income attributable to:</b>				
<b>Owners of the Company</b>				
Profit/ (loss) after tax	63,871	(702,093)	29,780	(278,530)
Other comprehensive income	73,493	(107,748)	(32,877)	(42,091)
	137,364	(809,840)	(3,098)	(320,621)
<b>Non-controlling interests</b>				
Profit/ (loss) after tax	238,138	56,060	208,966	101,641
Other comprehensive income	(4,881)	(8,026)	(11,188)	(12,407)
	233,256	48,034	197,778	89,234
<b>Total comprehensive income</b>	<b>370,620</b>	<b>(761,806)</b>	<b>194,680</b>	<b>(231,388)</b>

Advanced Chemical Industries PLC  
Consolidated statement of changes in equity  
Unaudited

Figures in '000' Taka

For the half year ended from July 2025 to December 2025

	Attributable to owners of the Company							Total equity
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	
Balance at 1 July 2025	878,318	1,309,016	-	1,671	(123,443)	223,658	7,853,786	9,767,815
Total comprehensive income	-	-	-	-	-	-	-	302,009
Profit/ (loss) after tax	-	-	-	-	-	-	-	238,138
Other comprehensive income, net of tax	-	-	-	-	13,559	59,934	-	(4,881)
Total comprehensive income	-	-	-	-	13,559	59,934	-	233,256
Transaction with owners of the Company	-	-	-	-	-	-	-	-
Stock dividend	-	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-	-
Total transactions with owners of the Company	-	-	-	-	-	-	-	-
Balance at 31 December 2025	878,318	1,309,016	-	1,671	(109,884)	283,591	7,853,786	9,629,701

For the half year ended from July 2024 to December 2024

	Attributable to owners of the Company							Total equity
	Share capital	Share premium	Merger consideration shares reserve	Capital reserve	Translation reserve	FVOCI reserve	Revaluation reserve	
Balance at 1 July 2024	762,056	1,254,116	56,854	1,671	(57,081)	272,821	5,852,066	8,557,727
Total comprehensive income	-	-	-	-	-	-	-	(646,033)
Profit/ (loss) after tax	-	-	-	-	-	-	-	56,060
Other comprehensive income, net of tax	-	-	-	-	(103,802)	(3,946)	-	(8,026)
Total comprehensive income	-	-	-	-	(103,802)	(3,946)	-	(8,026)
Transaction with owners of the Company	-	-	-	-	-	-	-	-
Issuance of merger consideration share	1,954	54,900	(56,854)	-	-	-	-	2,300
Stock dividend	114,602	-	-	-	-	-	-	-
Cash dividend	-	-	-	-	-	-	-	-
Capital contribution by non-controlling interests	-	-	-	-	-	-	-	-
Total transactions with owners of the Company	116,555	54,900	(56,854)	-	-	-	-	2,300
Balance at 31 December 2024	878,612	1,309,016	-	1,671	(160,883)	268,875	5,852,066	7,418,485

**Advanced Chemical Industries PLC**  
**Consolidated statement of cash flows**  
**Unaudited**

	Figures in '000' Taka	
	For the half year ended from	
	July 2025 to December 2025	July 2024 to December 2024
<b>Cash flows from operating activities</b>		
Cash receipts from customers and others	73,217,328	62,115,572
Cash paid to suppliers and employees	(71,540,147)	(61,908,021)
<b>Cash generated from / (used in) operating activities</b>	<b>1,677,181</b>	<b>207,551</b>
Paid to WPPF	(309,950)	(235,746)
Finance costs paid	(4,454,694)	(4,068,022)
Income tax paid	(1,347,988)	(1,489,652)
	(6,112,632)	(5,793,420)
<b>Net cash from / (used in) operating activities *</b>	<b>16 (a) (4,435,451)</b>	<b>(5,585,869)</b>
<b>Cash flows from investing activities</b>		
Acquisition of property, plant and equipment	(1,107,982)	(1,476,638)
Sale proceeds from property, plant and equipment	2,148	9,452
Purchase of biological assets	(7,005)	(6,746)
Dividend received	974,956	959,543
Short term investments	21,194	(5,365)
Long term investments	(753,647)	(164,457)
<b>Net cash from / (used in) investing activities</b>	<b>(870,336)</b>	<b>(684,211)</b>
<b>Cash flows from financing activities</b>		
Dividend paid to non-controlling interests	(39)	(13)
Payment for lease liabilities	(260,712)	(283,026)
Equity investment from NCI	15,000	-
Short-term borrowing received/(paid)	6,291,457	6,468,204
Long-term borrowing received/(paid)	(221,165)	(1,180,638)
<b>Net cash from / (used in) financing activities</b>	<b>5,824,542</b>	<b>5,004,527</b>
Net increase / (decrease) in cash and cash equivalents	518,758	(1,265,553)
Opening cash and cash equivalents	(4,788,759)	(3,107,509)
Effect of movements in exchange rates on cash held	119	1,520
<b>Closing cash and cash equivalents</b>	<b>(4,269,882)</b>	<b>(4,371,542)</b>
<b>Closing balance represents</b>		
Cash and cash equivalents	4,404,510	6,769,377
Bank overdraft	(8,674,392)	(11,140,919)
	<b>(4,269,882)</b>	<b>(4,371,542)</b>
<b>Net operating cash flow per share (NOCFPS) (in Taka)</b>	<b>18 (50.50)</b>	<b>(63.60)</b>

\*See Note 16(a) for reconciliation of consolidated net operating cash flow.

**Advanced Chemical Industries PLC**  
**Notes to the financial statements**  
**As at and for the 2nd quarter ended on 31 December 2025**  
**Unaudited**

1 Selected explanatory notes

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended from 1 July 2024 to 30 June 2025. This interim financial report includes only those selected explanatory notes as deemed appropriate for better understanding of unaudited financial statements.

2	Property, plant and equipment	31 December 2025	Figures in '000' Taka 30 June 2025
		Taka	Taka
	Opening balance	26,166,374	23,093,157
	Additions during the period	755,897	3,178,655
	Disposals and adjustments	(65,454)	(105,439)
	Accumulated depreciation	(6,181,542)	(5,782,707)
	Closing balance	20,675,275	20,383,667
2 (a)	Consolidated property, plant and equipment		
	Opening balance	51,344,389	45,716,051
	Additions during the period	1,133,253	5,774,182
	Disposals and adjustments	(82,991)	(145,844)
	Accumulated depreciation	(14,547,734)	(13,583,317)
	Closing balance	37,846,917	37,761,072
3	Investments		
	Investment in subsidiaries	1,962,638	1,962,638
	Investment in joint ventures	185,000	185,000
	Investment in associates	1,716,316	1,515,178
	Investment in shares	456,111	378,342
	Investment in FDR/ other deposits	825,202	270,536
	Impairment	(273,600)	(273,600)
		4,871,667	4,038,094
4	Inventories		
	Raw materials	4,064,467	4,105,615
	Packing materials	847,027	762,906
	Work-in-process	617,235	794,563
	Finished goods	4,202,977	3,378,905
	Goods in transit	1,090,534	870,725
	Stores and spares	234,827	209,948
	Allowance for inventory	(635,336)	(582,678)
		10,421,731	9,539,984

	31 December 2025	Figures in '000' Taka 30 June 2025
	Taka	Taka
4 (a) Consolidated inventories		
Raw materials	7,741,563	8,447,969
Packing materials	978,142	892,646
Work-in-process	859,945	1,047,247
Finished goods	15,218,788	12,576,827
Goods in transit	2,240,478	2,380,478
Stores and spares	414,713	393,669
Allowance for inventory	(1,346,375)	(1,188,969)
	<u>26,107,254</u>	<u>24,549,867</u>
5 Trade receivables		
Debts due over six months	1,557,897	1,640,365
Debts due below six months	4,916,456	3,812,733
Provision for doubtful debts	(807,760)	(807,958)
	<u>5,666,593</u>	<u>4,645,139</u>
5 (a) Consolidated trade receivables		
Debts due over six months	4,440,231	4,450,442
Debts due below six months	24,454,025	19,386,708
Provision for doubtful debts	(1,473,560)	(1,466,425)
	<u>27,420,696</u>	<u>22,370,726</u>
6 Inter-company receivables		
ACI Logistics Limited	16,979,200	15,401,817
ACI HealthCare Limited	17,590,370	16,025,590
ACI Foods Limited	2,530,211	2,029,096
ACI Biotech Limited	2,336,092	2,038,013
ACI Agrolink Limited	1,502,667	1,263,961
ACI HealthCare USA Inc.	1,110,260	1,167,606
INFOLYTX Bangladesh Ltd.	963,115	1,047,712
ACI Trade Services Limited	327,676	309,116
ACI Premio Plastics Limited	1,873,080	1,771,995
ACI Godrej Agrovvet Private Limited	935	948
Computer Technology Limited	30	30
	<u>45,213,637</u>	<u>41,055,886</u>
7 Advances, deposits and prepayments		
Advances to staff, suppliers and others	963,422	584,723
VAT current account	63,118	160,350
LC Margin	846,834	615,383
Deposits	348,542	312,281
Prepayments	301,461	138,434
	<u>2,523,377</u>	<u>1,811,171</u>

	<b>31 December 2025</b>	<b>Figures in '000' Taka</b>
	Taka	30 June 2025 Taka
7 (a) Consolidated advances, deposits and prepayments		
Advances to staff, suppliers and others	1,683,194	1,272,422
VAT current account	797,427	610,520
LC Margin	2,397,982	1,703,019
Deposits	964,211	927,379
Prepayments	418,359	249,495
Advance for capital expenditure	24,627	11,466
	<b>6,285,800</b>	<b>4,774,301</b>
8 Employee benefits		
Staff gratuity provision	1,387,280	1,395,788
Other long term employee benefits	381,550	366,489
	<b>1,768,830</b>	<b>1,762,277</b>
8 (a) Consolidated employee benefits		
Staff gratuity provision	1,760,892	1,725,747
Other long term employee benefits	526,534	506,333
	<b>2,287,426</b>	<b>2,232,080</b>
9 Long term borrowings		
Long term bank loans	1,846,671	1,523,822
	<b>1,846,671</b>	<b>1,523,822</b>
9 (a) Consolidated long term borrowings		
Long term bank loans	5,528,833	5,548,425
	<b>5,528,833</b>	<b>5,548,425</b>
10 Loans and borrowings - short term		
Short term loans	30,504,404	27,823,643
Current portion of long term loans	594,016	648,203
	<b>31,098,420</b>	<b>28,471,845</b>
10 (a) Consolidated loans and borrowings - short term		
Short term loans	58,692,387	51,426,823
Current portion of long term loans	3,669,603	4,047,183
	<b>62,361,990</b>	<b>55,474,007</b>
11 Inter company payables		
ACI Marine and Riverine Technologies Limited	32,005	28,863
ACI Motors Limited	491,258	488,754
ACI Herbal and Nutraceuticals Limited	104,581	83,244
ACI Salt Limited	2,240,406	1,776,982
ACI Pure Flour Limited	2,249,723	2,349,606
ACI Edible Oils Limited	124,892	155,555
Creative Communication Limited	499	12,101
ACI Formulations PLC	1,864,250	1,982,294
ACI Biosciences Limited	21,535	-
Stochastic Logic Limited	8,358	6,437
ACI Avionics and Airlines Services Limited	10,163	9,491
	<b>7,147,671</b>	<b>6,893,326</b>

	<b>31 December 2025</b>	<b>Figures in '000' Taka</b>
	Taka	<b>30 June 2025</b>
	Taka	Taka
12 Other payables		
Accruals	3,894,902	2,949,342
Advance from customers	108,084	80,056
Security money received from customers	21,580	22,100
Workers' profit participation fund	1,126,431	1,182,619
Tax and VAT deducted at source	163,553	168,138
Employees welfare fund	444,082	385,617
Rights share deposit to be refunded	564	564
Family day fund	9,997	8,917
Non-management staff provident fund	97,963	86,247
Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
Payable for redemption of Zero Coupon Bonds	20,403	20,403
Management staff provident fund	1,590	13,867
Advertisement and promotional funds	110,698	113,906
Development funds	12,292	13,547
Other finances	92,891	93,619
	<b>6,108,678</b>	<b>5,142,590</b>
12 (a) Consolidated other payables		
Accruals	8,162,976	6,399,969
Advance from customers	796,758	1,049,880
Security money received from customers	317,162	161,121
Workers' profit participation fund	1,736,012	1,699,638
Management staff provident fund	1,590	13,867
Tax and VAT deducted at source	477,573	338,111
Employees welfare fund	444,082	385,617
Rights share deposit to be refunded	564	564
Family day fund	9,997	8,917
Non-management staff provident fund	97,963	86,247
Unclaimed refund warrant - Zero Coupon Bonds	3,647	3,647
Payable for redemption of Zero Coupon Bonds	20,403	20,403
Creditors for capital expenditure	16,875	21,280
Advertisement and promotional funds	110,698	113,906
Development funds	44,552	13,547
Other finances	92,891	93,619
	<b>12,333,745</b>	<b>10,410,334</b>

		Figures in '000' Taka	
		For the half year ended from	
		July 2025 to December 2025 Taka	July 2024 to December 2024 Taka
13	Revenue		
	Pharmaceuticals	11,111,692	8,739,492
	Animal Health	3,389,815	2,714,090
	Consumer Brands	6,260,996	4,908,349
	Seed	1,148,234	1,266,059
	Fertilizer	1,540,086	1,295,928
	Flexible Packaging	3,309,841	3,213,899
	Animal Genetics and others	317,008	263,731
		<u>27,077,673</u>	<u>22,401,549</u>
13 (a)	Consolidated revenue		
	Gross sales	80,285,021	67,847,274
	Inter-company sales	(2,341,110)	(1,649,854)
		<u>77,943,911</u>	<u>66,197,421</u>
14	Cost of sales		
	Opening stock	9,041,989	8,580,500
	Purchase	14,933,953	12,489,472
		<u>23,975,942</u>	<u>21,069,972</u>
	Closing stock	(9,731,706)	(8,948,833)
		<u>14,244,236</u>	<u>12,121,139</u>
	Manufacturing expenses	2,643,653	1,815,452
		<u>16,887,888</u>	<u>13,936,591</u>
14 (a)	Consolidated cost of sales		
	Opening stock	22,966,540	20,478,216
	Purchase	54,411,211	48,522,374
		<u>77,377,752</u>	<u>69,000,590</u>
	Closing stock	(24,800,290)	(23,333,050)
		<u>52,577,462</u>	<u>45,667,540</u>
	Manufacturing expenses	4,587,243	3,867,128
		<u>57,164,705</u>	<u>49,534,668</u>
15	Administrative, selling and distribution expenses		
	Administrative expenses	608,896	450,226
	Distribution expenses	849,629	741,909
	Selling expenses	5,522,435	4,695,421
		<u>6,980,961</u>	<u>5,887,557</u>

		Figures in '000' Taka	
		For the half year ended from	
		July 2025	July 2024
		to	to
		December 2025	December 2024
		Taka	Taka
15 (a)	Consolidated administrative, selling and distribution expenses		
	Administrative expenses	1,787,185	1,345,902
	Distribution expenses	1,596,723	1,431,961
	Selling expenses	10,775,343	8,901,568
		<u>14,159,251</u>	<u>11,679,431</u>
16	Reconciliation of net operating cash flow		
	Profit after tax	2,980,788	2,377,556
	<i>Adjustment for non-cash items and others:</i>		
	-Unrealized gain on translation of foreign currency receivables	-	(34,960)
	- Depreciation and amortisation	464,208	352,004
	- Provisions	52,460	(143,652)
	- Finance cost	500,811	656,011
	- Tax expense	873,904	676,174
	- Contribution to WPPF	202,879	160,723
	-Lease and other adjustments	116,257	94,058
	<i>Changes in:</i>		
	- Inventories	(934,406)	(456,905)
	- Trade and other receivables	(2,189,100)	(1,755,375)
	- Advances, deposits and prepayments	(496,072)	(195,467)
	- Trade and other payables, and employment benefits	(111,754)	1,118,303
	Cash generated from operating activities	<u>1,459,975</u>	<u>2,848,577</u>
	Paid to WPPF	(272,960)	(209,270)
	Interest paid	(116,452)	(416,138)
	Income tax paid	(686,021)	(832,286)
	Net cash from operating activities	<u>384,542</u>	<u>1,390,883</u>
16 (a)	Reconciliation of consolidated net operating cash flow		
	Profit/ (loss) after tax	302,009	(646,033)
	<i>Adjustment for non-cash items and others:</i>		
	- Depreciation and amortisation	1,090,021	906,191
	- Provisions	164,541	(101,005)
	- Share of profit of equity accounted investees	(148,503)	(257,313)
	- Finance cost	4,921,919	4,436,700
	- Tax expense	1,450,342	1,404,579
	- Contribution to WPPF	321,764	253,341
	-Lease and other adjustments	269,816	435,874

<i>Changes in:</i>		
- Inventories	(1,714,792)	(2,920,420)
- Trade and other receivables	(5,087,599)	(3,705,427)
- Advances, deposits and prepayments	(739,421)	(2,380,338)
- Trade and other payables, and employment benefits	847,083	2,781,403
<b>Net cash from operating activities</b>	<b>1,677,181</b>	<b>207,551</b>
Paid to WPPF	(309,950)	(235,746)
Interest paid	(4,454,694)	(4,068,022)
Income tax paid	(1,347,988)	(1,489,652)
<b>Net cash from operating activities</b>	<b>(4,435,451)</b>	<b>(5,585,869)</b>

- 17 Consolidated operating segments  
Please see Annexure A.

<b>Figures in '000' Taka</b>	
<b>For the half year ended from</b>	
<b>July 2025</b>	<b>July 2024</b>
<b>to</b>	<b>to</b>
<b>December 2025</b>	<b>December 2024</b>

- 18 Consolidated EPS, NAV per share, and NOCFPS

Ordinary shares (Number)	87,832	87,832
<b>Weighted average number of ordinary shares (in thousand)</b>	<b>87,832</b>	<b>87,832</b>
Consolidated profit/ (loss) attributable to owners of the Company	63,871	(702,093)
Earnings per share (Taka)	0.73	(7.99)
Consolidated cash flows from operating activities (Taka '000)	(4,435,451)	(5,585,869)
Net operating cash flows per share (NOCFPS) (Taka)	(50.50)	(63.60)
	<b>31 December 2025</b>	<b>30 June 2025</b>
	<b>Taka</b>	<b>Taka</b>
Consolidated net asset attributable to owners of the Company (Taka '000)	7,966,713	8,048,929
Net asset value (NAV) per share	90.70	91.64

**Reasons for significant deviations:** During the half yearly ended on 31 December 2025, the Group achieved a 18% revenue growth which was contributed by a number of businesses as demonstrated in Consolidated Operating Segments in Annexure A. During the period, increase in gross profit exceeded the increase in operating expenses driven by growth in key segments. On the other hand, cost of borrowing increased due to the increase of interest rate along with the additional funding for working capital and strategic investments for supporting business growth. Overall, the consolidated EPS was Taka 0.73 during the period against Taka (7.99) of SPLY. NOCFPS during the period was Taka (50.50) against Taka (63.60) as a result of the movement in the working capital.

- 19 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

## Annexure-A

## Consolidated operating segments

Figures in '000' Taka  
For the half year ended from July 2025 to December 2025

Particulars	Reportable Segment											Total reportable segments	Unallocated/ Elimination	Total	
	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Flexible Packaging	Consumer Plastics				Healthcare
External revenue	11,111,692	3,389,815	6,066,568	2,492,093	20,819,832	3,168,119	14,893,220	1,798,450	4,931,738	2,933,504	1,437,469	-	73,042,500	4,901,411	77,943,911
Inter-segment revenue	-	-	585,533	-	287,653	120,039	54,972	62,284	230,758	376,337	-	473,617	2,191,194	149,916	2,341,110
Segment revenue	11,111,692	3,389,815	6,652,101	2,492,093	21,107,486	3,288,158	14,948,192	1,860,734	5,162,496	3,309,841	1,437,469	473,617	75,233,694	5,051,327	80,285,021
Depreciation and amortisation	258,403	15,855	51,993	15,762	102,932	17,498	94,433	60,843	44,400	89,473	48,590	220,670	1,020,852	69,169	1,090,021
Operating expenses	4,614,459	577,485	1,167,191	406,875	2,564,348	178,044	2,909,808	195,641	488,363	103,670	203,125	31,308	13,440,316	718,935	14,159,251
Finance cost / (income)	286,760	170,800	96,652	89,890	732,665	(75,691)	1,539,089	(91,579)	281,574	296,830	151,714	1,384,546	4,863,250	58,669	4,921,919
Segment profit/(loss) before tax	1,411,888	195,259	242,598	451,923	1,440,177	53,774	(1,267,406)	321,508	(116,528)	147,394	(83,452)	(1,386,309)	1,410,827	341,524	1,752,351
Segment assets at 31 December 2025	17,854,778	2,981,933	5,819,107	4,136,230	35,993,723	3,702,187	8,196,174	4,477,048	4,035,688	5,823,499	1,457,025	7,931,638	102,409,029	10,834,191	113,243,220
Segment liabilities at 31 December 2025	6,544,805	1,831,918	4,091,361	1,851,557	23,252,996	2,130,416	30,411,950	1,469,373	6,258,519	24,137	2,134,220	23,650,477	103,651,729	(38,209)	103,613,520

For the half year ended from July 2024 to December 2024

Particulars	Reportable segment											Total reportable segments	Unallocated/ Elimination	Total	
	Pharmaceuticals	Animal Health	Consumer Brands	Crop Care and Public Health	Motors	Pure Flour	Retail Chain	Salt	Foods	Flexible Packaging	Consumer Plastics				Healthcare
External revenue	8,739,492	2,714,090	4,745,142	2,273,215	16,950,003	3,481,223	12,304,266	1,372,997	4,690,843	2,964,636	1,501,758	537,014	62,274,679	3,922,742	66,197,421
Inter-segment revenue	-	-	494,935	-	48,484	223,182	42,942	31,590	177,434	249,264	-	273,229	1,541,060	108,794	1,649,854
Segment revenue	8,739,492	2,714,090	5,240,077	2,273,215	16,998,486	3,704,405	12,347,208	1,404,588	4,868,276	3,213,899	1,501,758	810,243	63,815,738	4,031,536	67,847,274
Depreciation and amortisation	169,418	14,993	40,927	12,100	68,578	17,097	86,833	49,200	47,143	86,684	48,603	194,148	835,723	70,468	906,191
Operating expenses	3,879,594	548,376	1,000,099	342,910	2,038,821	145,082	2,240,691	140,886	407,586	95,739	256,769	41,621	11,138,173	541,257	11,679,431
Finance cost / (income)	271,880	131,900	73,380	114,244	467,782	(37,012)	1,418,701	(69,165)	291,604	330,382	139,842	1,273,949	4,407,488	29,213	4,436,700
Segment profit/(loss) before tax	866,513	159,825	155,418	473,843	1,098,945	69,151	(1,262,076)	157,330	(132,596)	83,159	(91,635)	(1,428,194)	149,682	608,864	758,546
Segment assets at 30 June 2025	16,156,146	2,816,931	5,648,910	3,316,182	30,605,133	4,066,045	7,127,316	4,291,047	3,080,586	7,052,355	1,416,045	8,135,032	93,711,727	10,274,513	103,986,240
Segment liabilities at 30 June 2025	4,992,495	1,514,435	4,190,669	1,669,320	18,455,038	2,513,424	28,064,598	1,515,381	5,180,865	6,414,922	1,987,497	22,454,294	98,952,937	(4,734,512)	94,218,425